We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Microchip Imaging Cytometry Makes Laboratory Testing More Economical, Easy-to-Use and Accessible

By LabMedica International staff writers
Posted on 25 Aug 2022
Image: MIC could change the landscape of the clinical lab testing field (Photo courtesy of OEA)
Image: MIC could change the landscape of the clinical lab testing field (Photo courtesy of OEA)

The economic globalization and the aging population of many countries in the world generate an enormous need for rapid and cost-effective point-of-need laboratory tests. Over the past two years, the entire world has been tackling challenges from COVID-19 pandemic. The general population in many countries are routinely taking nucleic acid tests and/or rapid antigen tests for screening purposes. Healthcare workers are in need of more economical, and easy-to-use diagnostic testing tools to support their healthcare practice. Public health agencies also need powerful diagnostic tools to help them make critical policy decisions. In a typical clinic appointment, laboratory tests go through procedures such as lab requisition, sample collection, sample processing, and reporting. The average turn-around-time may vary from several hours to several days. For many disease diagnoses and monitoring requiring instant information and rapid decision-making, the traditional technology and workflow could not effectively meet the clinical needs.

Meanwhile, there is the “rapid test strip” option such as the COVID antigen test strip and the hCG pregnancy test strip that provides instant test results. These rapid test strips become an important diagnostic tool for screening and monitoring, although the application of the test strips is usually restricted to qualitative tests. Additionally, because of their relatively lower analytical sensitivity, these rapid test strips could not detect biomarkers that have a low quantity in the specimen. Therefore, there is a growing need to develop a quantitative, easy-to-use, and accessible diagnostic instrument and reagents. Given the emerging healthcare needs, scientists and engineers continuously come up with creative diagnostic solutions using a variety of technological approaches. Among these technologies, microfluidics becomes a highly valuable approach to potentially address many of the requirements. Microchip imaging cytometry (MIC) based on microfluidic technologies is such an innovative analytical platform that may change the landscape of the clinical lab testing field.

A team of researchers at the University of Toronto (Toronto, ON, Canada) have published a paper in Opto-Electronic Advances (OEA) that addresses scientific and technical advances in the field of MIC and shows the applications of MIC that may bring more economical, easy-to-use, and accessible healthcare to the public. MIC is a platform technology that can rapidly detect and analyze human biochemical substances such as cells, proteins, and nucleic acids. MIC devices have the attributes of portability, cost-effectiveness, and adaptability while providing quantitative measurements to meet the needs of laboratory testing in a variety of healthcare settings. Based on the use of microfluidic chips, MIC requires less sample and may complete sample preparation automatically. Therefore, they can provide quantitative testing results simply using a finger prick specimen. The decreased reagent consumption and reduced form factor also help improve the accessibility and affordability of healthcare services in remote and resource-limited settings.

The article reviews notable clinical applications of MIC technologies, such as HIV-patient monitoring, sickle disease screening, infectious disease diagnosis, etc. Depending on the level of automation and image capturing formats, MIC devices were classified into three approaches: Static-chip-static-fluid (SCSF), Static-chip-moving-fluid (SCMF) and Moving-chip-static-fluid (MCSF). Brightfield imaging, fluorescence imaging, and lens-free imaging techniques have been adopted in MIC systems. Image acquisition techniques such as time delay integration and temporally coded excitation were demonstrated to achieve higher sensitivity in detecting fast-moving objects in low light levels.

Compared with traditional flow cytometers, MIC analyzes objects such as cells and particles through a relatively wide and shallow microfluidic chip channel. As a result of the breakthrough development of semiconductor sensor devices and information technology in recent years, the light source and imaging detection components of MIC can also achieve higher optoelectronic performance. Thanks to the innovation and development of biotechnology, micro-nano manufacturing, semiconductor materials, information technology, and other fields, MIC will find more important clinical test applications in the future, and promote the development of more economical, easy-to-use, and accessible point-of-need tests. Recent advances in photonics, integrated optics, and imaging technologies promise to increase the sensitivity and functionality of MIC systems while decreasing their size and cost. Colors can be differentiated directly on the silicon CMOS image sensors using several techniques. Progress towards higher sensitivity detectors has also been made by integrating single-photon avalanche diodes in standard CMOS with microfluidic systems.

The development of MIC devices should focus on the following aspects: 1) the device should be portable to fit the diagnostic purpose in varying healthcare scenarios, 2) the device should be easy to use and provide sample-to-answer results rapidly (e.g. 15 minutes), 3) the microfluidic assembly should contain pre-loaded reagents and be disposable. Additionally, the analytical performance of MIC devices, such as sensitivity, accuracy, precision, robustness, needs to meet the certain testing requirements. In the process of instrument and reagent design and development, all these aspects need to be considered. Therefore, engineering design and development need to find the sophisticated balance between complexity, performance and cost, to meet the needs in healthcare and to benefit more patients.

 

 

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Gold Member
Platelet Function Analyzer
PL-12

Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more